Dementia Drugs Market Overview
Dementia drugs are primarily used to manage symptoms associated with dementia, such as cognitive decline, memory loss, and behavioral changes. These medications work by regulating neurotransmitters, slowing disease progression, or alleviating symptoms, though they do not cure dementia. The market is growing due to the increasing prevalence of dementia globally, coupled with the rising aging population. Innovative treatments and therapies, alongside government support, are driving this market’s expansion. Additionally, advancements in research and drug development are enhancing the therapeutic landscape for dementia, presenting opportunities for market growth in the coming years.
Key Findings
- The FDA’s Accelerated Approval of Leqembi (lecanemab-irmb) in January 2023 represented a breakthrough in dementia drug development. This advancement, targeting the underlying amyloid plaques in Alzheimer’s, drove significant growth in the dementia drug market.
- In August 2023, CervoMed completed its merger with EIP Pharma, advancing neflamapimod for dementia with Lewy bodies. Collaborations and acquisitions between some of the affluent market players is one of the major market trends.
- The market growth is further driven by increased venture capital investments. For example, in March 2025, SV Health Investors raised USD 250 million for its second dementia discovery fund to advance first-in-class dementia therapeutics.
Dementia Drugs Market Demand Drivers
The dementia drugs market is witnessing accelerated growth, driven by strategic acquisitions and therapeutic advancements in Alzheimer’s disease. In October 2024, AbbVie announced a USD 1.4 billion acquisition of Aliada Therapeutics, enhancing its neuroscience pipeline with ALIA-1758, an innovative antibody capable of crossing the blood-brain barrier to target amyloid beta. Additionally, in July 2024, the United States FDA approved Eli Lilly’s Kisunla, a groundbreaking therapy that demonstrated a 35% reduction in cognitive and functional decline during Phase 3 trials. These developments are significantly strengthening the market outlook and fostering continued investment in disease-modifying treatments.
Dementia Drugs Market Segmentation Analysis
Cholinesterase Inhibitors to Hold Significant Value for Segmentation by Drug Class
The types of drug classes involved in the market are MAO inhibitors, glutamate inhibitors, cholinesterase inhibitors, and others. Among these, cholinesterase inhibitors are expected to dominate due to their proven effectiveness in managing Alzheimer’s cognitive symptoms and strong regulatory support. For instance, in December 2023, Alpha Cognition announced FDA acceptance of its New Drug Application for ALPHA-1062, a new acetylcholinesterase inhibitor for mild-to-moderate Alzheimer’s disease, highlighting ongoing innovation in this class.
The market report also offers insights based on the indications, route of administration, end user, distribution channel, and region.
Dementia Drugs Market: Competitive Landscape
- In January 2025, Johnson & Johnson, headquartered in New Brunswick, New Jersey, and founded in 1886, advanced its commitment to the dementia drugs market with two U.S. FDA Fast Track designations for investigational Alzheimer’s disease, the most common form of dementia. Posdinemab and JNJ-2056 both target pathological tau proteins, aiming to slow disease progression in early and preclinical stages. These developments reflect the company’s expanding role in addressing dementia-related neurodegeneration.
- In July 2024, Eli Lilly and Company, headquartered in Indianapolis, Indiana, received FDA approval for Kisunla (donanemab-azbt) as a treatment for early symptomatic Alzheimer's disease. Kisunla is the first amyloid plaque-targeting therapy with evidence supporting limited-duration treatment based on plaque removal, offering a significant breakthrough in the dementia drugs market by slowing cognitive decline and reducing amyloid plaques.
- Other players involved in the market include Teva Pharmaceutical Industries Ltd., Aurobindo Pharma, Zydus Cadila, Eisai Co., Ltd., Novartis AG, Biogen, Otsuka Pharmaceutical Co., Ltd., and Corium Inc.
Dementia Drugs Market Analysis by Region
North America is Projected to Lead the Market Share
The market segmentation by region includes the United States, Germany, France, Italy, Spain, the United Kingdom, Japan, and India. Among these, the United States is expected to lead the market share due to its high prevalence of dementia, robust healthcare infrastructure, and significant investment in pharmaceutical research. Supportive regulatory frameworks and ongoing clinical trials further drive innovation.
Key Offerings of the Report
- The EMR report gives an overview of the market for Dementia Drugs for the period (2018-2024) and (2025-2034).
- The report also offers historical (2018-2024) and forecast (2025-2034) market information for the indications, drug class, route of administration, end user, distribution channel, and region of the market.
- The report analyses the market dynamics, covering the key demand and price indicators in the market, along with providing an assessment of the SWOT and Porter’s Five Forces models.
About Us
Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which is constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.
EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.
Contact Us
Expert Market Research
Website: www.expertmarketresearch.com
Email: [email protected]
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790
